Coherus BioSciences, Inc. (CHRS) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Coherus BioSciences, Inc. (CHRS) Bundle
Simplify Coherus BioSciences, Inc. (CHRS) valuation with this customizable DCF Calculator! Featuring real Coherus BioSciences, Inc. (CHRS) financials and adjustable forecast inputs, you can test scenarios and uncover Coherus BioSciences, Inc. (CHRS) fair value in minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 356.1 | 475.8 | 326.6 | 211.0 | 257.2 | 250.0 | 243.0 | 236.2 | 229.6 | 223.1 |
| Revenue Growth, % | 0 | 33.63 | -31.37 | -35.37 | 21.89 | -2.8 | -2.8 | -2.8 | -2.8 | -2.8 |
| EBITDA | 111.0 | 161.8 | -260.7 | -255.6 | -193.9 | -95.0 | -92.4 | -89.8 | -87.3 | -84.8 |
| EBITDA, % | 31.18 | 34.01 | -79.83 | -121.1 | -75.39 | -38.01 | -38.01 | -38.01 | -38.01 | -38.01 |
| Depreciation | 3.3 | 5.0 | 5.7 | 3.7 | 3.8 | 3.5 | 3.4 | 3.3 | 3.2 | 3.1 |
| Depreciation, % | 0.91527 | 1.04 | 1.73 | 1.75 | 1.47 | 1.38 | 1.38 | 1.38 | 1.38 | 1.38 |
| EBIT | 107.8 | 156.9 | -266.3 | -259.3 | -197.7 | -97.6 | -94.9 | -92.2 | -89.6 | -87.1 |
| EBIT, % | 30.27 | 32.97 | -81.56 | -122.86 | -76.86 | -39.04 | -39.04 | -39.04 | -39.04 | -39.04 |
| Total Cash | 177.7 | 541.2 | 417.2 | 191.7 | 117.7 | 193.3 | 187.8 | 182.6 | 177.5 | 172.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 142.0 | 157.0 | 123.0 | 110.0 | 260.5 | 131.3 | 127.7 | 124.1 | 120.6 | 117.2 |
| Account Receivables, % | 39.88 | 33.01 | 37.67 | 52.11 | 101.27 | 52.53 | 52.53 | 52.53 | 52.53 | 52.53 |
| Inventories | 55.1 | 92.2 | 93.3 | 115.1 | 62.6 | 71.1 | 69.1 | 67.2 | 65.3 | 63.5 |
| Inventories, % | 15.47 | 19.37 | 28.56 | 54.52 | 24.34 | 28.45 | 28.45 | 28.45 | 28.45 | 28.45 |
| Accounts Payable | 26.0 | 15.2 | 16.2 | 11.5 | 35.2 | 17.3 | 16.8 | 16.3 | 15.9 | 15.4 |
| Accounts Payable, % | 7.3 | 3.19 | 4.95 | 5.46 | 13.69 | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 |
| Capital Expenditure | -12.9 | -7.1 | -1.3 | -2.0 | -.3 | -3.3 | -3.2 | -3.1 | -3.0 | -2.9 |
| Capital Expenditure, % | -3.62 | -1.48 | -0.39473 | -0.96616 | -0.11118 | -1.32 | -1.32 | -1.32 | -1.32 | -1.32 |
| Tax Rate, % | 0.15948 | 0.15948 | 0.15948 | 0.15948 | 0.15948 | 0.15948 | 0.15948 | 0.15948 | 0.15948 | 0.15948 |
| EBITAT | 104.4 | 152.9 | -284.2 | -290.3 | -197.4 | -96.5 | -93.8 | -91.1 | -88.6 | -86.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -76.4 | 87.8 | -245.9 | -302.0 | -268.3 | 6.4 | -88.4 | -85.9 | -83.5 | -81.2 |
| WACC, % | 8.06 | 8.1 | 8.27 | 8.27 | 8.26 | 8.19 | 8.19 | 8.19 | 8.19 | 8.19 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -253.1 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -83 | |||||||||
| Terminal Value | -1,336 | |||||||||
| Present Terminal Value | -901 | |||||||||
| Enterprise Value | -1,155 | |||||||||
| Net Debt | 378 | |||||||||
| Equity Value | -1,532 | |||||||||
| Diluted Shares Outstanding, MM | 94 | |||||||||
| Equity Value Per Share | -16.27 |
What You Will Get
- Real CHRS Financial Data: Pre-filled with Coherus BioSciences’ historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Coherus BioSciences’ intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Real-Life CHRS Data: Pre-filled with Coherus BioSciences’ historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your adjustments.
- Scenario Testing: Develop multiple forecasting scenarios to evaluate different valuation results.
- User-Friendly Design: Intuitive, organized, and crafted for both professionals and novices.
How It Works
- 1. Access the Model: Download and open the Excel file featuring Coherus BioSciences, Inc. (CHRS) preloaded data.
- 2. Adjust Key Variables: Modify essential inputs such as revenue growth, discount rate, and research and development expenses.
- 3. Analyze Results in Real-Time: The DCF model automatically computes intrinsic value and net present value (NPV).
- 4. Explore Different Scenarios: Evaluate various projections to assess different valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation analysis to reinforce your strategic decisions.
Why Choose This Calculator for Coherus BioSciences (CHRS)?
- Accuracy: Leveraging real Coherus financials for precise data representation.
- Flexibility: Tailored for users to easily experiment and adjust inputs.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply them using real-world case studies from Coherus BioSciences (CHRS).
- Researchers: Integrate advanced biopharmaceutical models into your studies or publications.
- Investors: Validate your investment strategies and assess the market potential of Coherus BioSciences (CHRS).
- Analysts: Enhance your analysis with a comprehensive, customizable financial model tailored for biotech firms.
- Healthcare Entrepreneurs: Understand how established biotech companies like Coherus BioSciences (CHRS) navigate the market.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring extensive valuation calculations.
- Real-World Data: Coherus BioSciences’ historical and projected financials preloaded for analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore different scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Charts and tables to present clear, actionable results.